Literature DB >> 16167197

Hepatic encephalopathy: a dynamic or static condition.

Charmaine A Stewart1, Jane Cerhan.   

Abstract

Hepatic encephalopathy (HE) is a neuropsychiatric disorder associated with portal hypertension. The mechanism of this disorder is still being characterized and the management has relied primarily on lowering the amount of ammonia present in the gastrointestinal tract or reversing liver disease by replacing the diseased liver. It is, however, not established that all the effects of hepatic encephalopathy are reversed by liver transplantation. In this review, we have outlined the mechanisms underlying HE and the pros and cons of reversibility of HE.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16167197     DOI: 10.1007/s11011-005-7207-x

Source DB:  PubMed          Journal:  Metab Brain Dis        ISSN: 0885-7490            Impact factor:   3.584


  70 in total

1.  Minimal hepatic encephalopathy: longitudinal effects of liver transplantation.

Authors:  Katia Mattarozzi; Andrea Stracciari; Luca Vignatelli; Roberto D'Alessandro; Maria Cristina Morelli; Maria Guarino
Journal:  Arch Neurol       Date:  2004-02

2.  Hyperammonemia impairs NMDA receptor-dependent long-term potentiation in the CA1 of rat hippocampus in vitro.

Authors:  M D Muñoz; P Monfort; J M Gaztelu; V Felipo
Journal:  Neurochem Res       Date:  2000-04       Impact factor: 3.996

3.  Neuropsychological aspects of portal-systemic encephalopathy.

Authors:  H Schomerus; W Hamster
Journal:  Metab Brain Dis       Date:  1998-12       Impact factor: 3.584

4.  Transjugular intrahepatic portosystemic shunts compared with endoscopic sclerotherapy for the prevention of recurrent variceal hemorrhage. A randomized, controlled trial.

Authors:  A J Sanyal; A M Freedman; V A Luketic; P P Purdum; M L Shiffman; P E Cole; J Tisnado; S Simmons
Journal:  Ann Intern Med       Date:  1997-06-01       Impact factor: 25.391

Review 5.  Evidence for an astrocytic glutamate transporter deficit in hepatic encephalopathy.

Authors:  H Chan; R F Butterworth
Journal:  Neurochem Res       Date:  1999-11       Impact factor: 3.996

6.  Long-term changes in glial fibrillary acidic protein and glutamine synthetase immunoreactivities in the supraoptic nucleus of portacaval shunted rats.

Authors:  I Suárez; G Bodega; E Arilla; B Fernández
Journal:  Metab Brain Dis       Date:  1996-12       Impact factor: 3.584

7.  Manganese deposition in basal ganglia structures results from both portal-systemic shunting and liver dysfunction.

Authors:  C Rose; R F Butterworth; J Zayed; L Normandin; K Todd; A Michalak; L Spahr; P M Huet; G Pomier-Layrargues
Journal:  Gastroenterology       Date:  1999-09       Impact factor: 22.682

8.  Brain indoles in human hepatic encephalopathy.

Authors:  H al Mardini; E J Harrison; P G Ince; K Bartlett; C O Record
Journal:  Hepatology       Date:  1993-06       Impact factor: 17.425

9.  Latent portasystemic encephalopathy. I. Nature of cerebral functional defects and their effect on fitness to drive.

Authors:  H Schomerus; W Hamster; H Blunck; U Reinhard; K Mayer; W Dölle
Journal:  Dig Dis Sci       Date:  1981-07       Impact factor: 3.199

10.  Manganese induces the mitochondrial permeability transition in cultured astrocytes.

Authors:  Kakulavarapu V Rama Rao; Michael D Norenberg
Journal:  J Biol Chem       Date:  2004-06-01       Impact factor: 5.157

View more
  2 in total

1.  Portosystemic encephalopathy due to mesoiliac shunt in a patient without cirrhosis.

Authors:  Sobia Ali; Alan H Stolpen; Warren N Schmidt
Journal:  J Clin Gastroenterol       Date:  2010 May-Jun       Impact factor: 3.062

2.  Delayed-onset hepatic encephalopathy induced by zolpidem: a case report.

Authors:  Vitor Carlos Santos da Silva; Paulo Lisboa Bittencourt; Sylvania Pinho; Andréa Ribeiro Cavalcanti; Cláudio Celestino Zollinger
Journal:  Clinics (Sao Paulo)       Date:  2008-08       Impact factor: 2.365

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.